Meicoxia Adverse Reactions

Blood and lymphatic system disorders: thrombocytopenia.
Infections and infestation: gastroenteritis, upper respiratory infection, urinary tract infection.
Immune system disorders: hypersensitivity reactions, including angioedema, anaphylactic/anaphylactoid reactions including shock.
Metabolism and nutrition disorders: appetite increase or decrease, weight gain, hyperkalemia.
Psychiatric disorders: anxiety, depression, mental acuity decreased, confusion, hallucinations, restlessness.
Nervous system disorders: dysgeusia, insomnia, paresthesia/hypaesthesia, somnolence.
Eye disorders: blurred vision.
Ear and labyrinth disorders: tinnitus.
Cardiac disorders: congestive heart failure, non-specific ECG changes, myocardial infarction, palpitations, angina, arrhythmia.
Vascular disorders: flushing, cerebrovascular accident, hypertensive crisis.
Respiratory, thoracic and mediastinal disorders: cough, dyspnea, epistaxis, bronchospasm.
Gastrointestinal disorders: abdominal distention, acid reflux, bowel movement pattern change, constipation, dry mouth, gastroduodenal ulcer, irritable bowel syndrome. Oesophagitis, oral ulcers, peptic ulcers including perforation and bleeding (mainly in elderly patients), vomiting, gastritis.
Hepatobiliary disorders: hepatitis, jaundice, hepatic failure.
Skin and subcutaneous tissue disorders: ecchymosis facial oedema, pruritus, erythema, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticarial, fixed drug eruption.
Musculoskeletal, connective tissue and bone disorder: muscular cramp/spasm, musculoskeletal pain/stiffness.
Renal and urinary disorders: proteinuria, renal insufficiency, including renal failure.
General disorder and administration site conditions: chest pain.
Investigation: blood urea nitrogen increased, creatine phosphokinase increased, haematocrit decreased, haemoglobin decreased, hyperkalaemia, leukocytes decreased, platelets decreased, serum creatinine increased, uric acid increased.
The following serious undesirable effects have been reported in association with the use of NSAIDs and cannot be ruled out for etoricoxib: nephrotoxicity including interstitial nephritis and nephrotic syndrome; hepatotoxicity, including hepatic failure.